These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31080107)

  • 41. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
    Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
    Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent strategies targeting HIV glycans in vaccine design.
    Horiya S; MacPherson IS; Krauss IJ
    Nat Chem Biol; 2014 Dec; 10(12):990-9. PubMed ID: 25393493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD8
    Collins DR; Gaiha GD; Walker BD
    Nat Rev Immunol; 2020 Aug; 20(8):471-482. PubMed ID: 32051540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elucidating the elite: mechanisms of control in HIV-1 infection.
    O'Connell KA; Bailey JR; Blankson JN
    Trends Pharmacol Sci; 2009 Dec; 30(12):631-7. PubMed ID: 19837464
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current views on the potential for development of a HIV vaccine.
    Cohen KW; Frahm N
    Expert Opin Biol Ther; 2017 Mar; 17(3):295-303. PubMed ID: 28095712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines.
    Hassapis KA; Stylianou DC; Kostrikis LG
    Viruses; 2014 Dec; 6(12):5047-76. PubMed ID: 25525909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. T cell immune responses to HIV-1.
    Vasan S; Schlesinger SJ; Arrode G
    Front Biosci; 2007 Jan; 12():2330-43. PubMed ID: 17127243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging concepts on the role of innate immunity in the prevention and control of HIV infection.
    Ackerman ME; Dugast AS; Alter G
    Annu Rev Med; 2012; 63():113-30. PubMed ID: 22077718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Host controls of HIV broadly neutralizing antibody development.
    Kelsoe G; Haynes BF
    Immunol Rev; 2017 Jan; 275(1):79-88. PubMed ID: 28133807
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
    Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
    PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.
    Haut LH; Ertl HC
    J Leukoc Biol; 2009 Oct; 86(4):779-93. PubMed ID: 19597003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A brief history of the global effort to develop a preventive HIV vaccine.
    Esparza J
    Vaccine; 2013 Aug; 31(35):3502-18. PubMed ID: 23707164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvants: tailoring humoral immune responses.
    McElrath MJ
    Curr Opin HIV AIDS; 2017 May; 12(3):278-284. PubMed ID: 28257301
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vaccines and vaccine strategies against HIV.
    Stratov I; DeRose R; Purcell DF; Kent SJ
    Curr Drug Targets; 2004 Jan; 5(1):71-88. PubMed ID: 14738219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methanobrevibacter smithii archaeosomes-entrapped mzNL4-3 virus-like particles induce specific T helper 1-oriented cellular and humoral responses against HIV-1.
    Salmani AS; Aghasadeghi MR; Nategh R; Mokhtari-Azad T; Siadat SD
    Curr HIV Res; 2013 Sep; 11(6):491-7. PubMed ID: 24329177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant.
    Menon V; Ayala VI; Rangaswamy SP; Kalisz I; Whitney S; Galmin L; Ashraf A; LaBranche C; Montefiori D; Petrovsky N; Kalyanaraman VS; Pal R
    J Gen Virol; 2017 Aug; 98(8):2143-2155. PubMed ID: 28758637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.
    Tritel M; Stoddard AM; Flynn BJ; Darrah PA; Wu CY; Wille U; Shah JA; Huang Y; Xu L; Betts MR; Nabel GJ; Seder RA
    J Immunol; 2003 Sep; 171(5):2538-47. PubMed ID: 12928404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
    Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
    Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
    Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.